Spondyloarthritis & psoriatic arthritis
Profiling of immunoglobulin G (IgG) N-glycosylation for axial spondyloarthritis and other rheumatic diseases
Authors' conclusion
Specific IgG N-glycans hold potential as novel biomarkers to enhance diagnosis and disease activity assessment in axSpA management.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA), SLE, RA, OA or gout, and healthy controls; serum IgG N-glycome analysed by ultra-performance liquid chromatography
- Participants
- 138 / 102 / 106 / 33 / 41 / 117
- Comparison
- axSpA vs healthy controls and four other rheumatic diseases
- axSpAn = 138
- SLEn = 102
- RAn = 106
- OAn = 33
- Goutn = 41
- Healthy controlsn = 117reference
- Outcome
- Association of IgG N-glycan profiles with diagnosis and disease activity of axSpA
Methodological detailsclinical case-control
- Clinical case-control
Main finding
As reported in the abstract
IgG N-glycans associated with axSpA
axSpA vs Healthy controlsAdjusted odds ratio (95% CI)
FA2
5.62(3.41–9.24)
FA2 [3]G1
0.33(0.22–0.50)
Observational data: associations, not effects.
Further findings
Characteristic and unique IgG N-glycans across diseases
- Decreased FA2 [3]G1 associated with all five studied rheumatic diseases
- Decreased FA2BG2S2 unique in differentiating axSpA from the other four rheumatic diseases
FA2 and axSpA disease activity
- FA2 positively associated with ASDAS-CRP, SPARCC-SIJ and SPARCC-spine
Canonical correlation of IgG N-glycans (FA2 [3]G1, FA2BG2S2, FA2) with inflammatory cytokines (IL-23, TNF α) in axSpA
- Canonical correlation r
- 0.519
- P
- P = 0.017
Original publication
Profiling of IgG N-glycosylation for axial spondyloarthritis and other rheumatic diseases. Arthritis Res Ther. Published 22 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →